The study of lymphangiogenesis is an emerging field of research for defining the fundamental mechanisms of lymphatic vessel growth and function under physiological and pathological conditions. 1, 2 This knowledge serves as the key to therapeutic applications for both blocking and promoting lymphangiogenesis. For example, an association between intra-or peritumoral lymphangiogenesis with lymphatic metastasis in many cancers [3] [4] [5] suggests that newly formed lymphatics serve as conduits for lymphatic invasion and spread of cancer cells to lymph nodes. This is often the first route of spread in many cancers that can subsequently metastasize from the lymph nodes to other organs via the blood stream. Thus, inhibition of lymphangiogenesis might offer a new opportunity for intervention of metastasis. Conversely, dysfunction of lymphatic vessels often leads to primary and secondary lymphedema, which markedly impairs the function of affected tissues or organs. Thus, delivery of lymphangiogenic factors to these affected tissues or organs might restore their functions by establishing functional lymphatic networks. 6 Research on lymphangiogenesis was long limited by the lack of lymphatic-specific markers and suitable experimental models. Anatomical identification of the lymphatic system in small animals, generation of transgenic mouse models and recent in vitro models of culturing lymphatic endothelial cells (LECs) or lymphatic vessel explants have all paved the way for a new era in this research. 7 Numerous in vitro systems have been developed to study lymphangiogenesis utilizing LECs from various sources: 7 (a) lymphatic-rich lesions induced by injecting Freund's adjuvant, (b) explants of thoracic duct fragments, (c) LEC differentiation induced in embryoid bodies and (d) immune-purified primary or immortalized human dermal LEC. LECs, when placed on collagen gel or matrigel, align themselves to form tube-like structures under appropriate stimuli. 8 However, most of these systems suffer from limitations including the short life or limited number of primary cells, or possible non-physiological nature of immortalized cells. In a more physiological, organotypic model of thoracic duct rings explanted in collagen gels allows lymphatic capillary-like sprouting under stimulated conditions, which can be quantified by computerassisted imaging. 7 In our experience, this assay is time-and labor-intensive, requiring the death of many young mice of identical strain and sex for harvesting thoracic ducts, and low oxygen culture conditions that require standardization. None of these in vitro assays can adequately address the issues of realtime quantification of the growth of lymphatic vessels in vivo, with lumens and lymphatic stability, which are essential for the maintenance of lymphatic functions. For these reasons, a reliable, quick and powerful in vivo lymphangiogenesis assay is urgently needed.
Unlike blood vessels, lymphatics are not perfused with red blood cells and thus remain poorly visible in a given tissue. Their macroscopic detection is facilitated by the uptake of dyes such as Evans Blue or India ink from the extravascular space. 9 At the microscopic level, immunohistochemical staining for specific markers such as lymphatic vessel endothelial hyaluronan receptor-1 (Lyve1), vascular endothelial growth factor receptor 3 (VEGFR3) or Podoplanin (Pdpn) or PROX-1 (Prox1) provides an opportunity for visualization of lymphatic microvessels. [10] [11] [12] [13] Examples of in vivo models manipulating lymphangiogenesis include (a) induction of tumor-associated lymphangiogenesis by VEGF-C or -D overexpression in tumor cells 8, 14, 15 or in transgenic mice, 16, 17 (b) lymphatic hyperplasia induced by intraperitoneal injection of incomplete Freund's adjuvant, 18 (c) implantation of growth factor-containing pellets into corneal micropockets 19, 20 and (d) the use of avian chorioallantoic membrane (CAM) to stimulate lymphangiogenesis. 21 Each assay has its own advantages and limitations depending on the objectives. However, some of them may include masking effects, for example, of native embryonic lymphangiogenesis in the CAM assay, or of inflammatory mediators produced by injection of incomplete Freund's adjuvant. Furthermore, many of these in vivo assays are time consuming and often qualitative, or at best, semiquantitative. To overcome these limitations, we have developed a quick, practical and quantitative in vivo assay for measuring lymphangiogenesis by implanting angioreactors in the mouse dorsal flanks. This method, an adaptation of the directed in vivo angiogenesis assay (DIVAA), [22] [23] [24] is highly reproducible, providing an opportunity to quantify accurately lymphangiogenesis as early as 10 days. It is applicable to many objectives including quick preclinical screening of drugs in vivo. We name this method as 'directed in vivo lymphangiogenesis assay' (DIVLA). To illustrate its power, here we used a human breast cancer cell line MDA-MB-468LN, expressing high levels of VEGF-D but little VEGF-C or VEGF-A, and its VEGF-D-silenced derivative, to quantitate VEGF-D-dependent, tumor-associated lymphangiogenesis in nude mice. To reproduce DIVLA in immunocompetent mice, we used a syngeneic murine breast cancer cell line C3L5 that produced VEGF-C and -D in a cyclo-oxygenase (COX)-2-dependent manner. 25 
MATERIALS AND METHODS Human Cell lines
Human breast cancer cell line MDA-MB-468LN (henceforth called 468LN) is a lymphatic metastatic variant of the MDA-MB-468 line. 26 Cells were used from the original stock shortly after their generation. We established stable VEGF-D knocked down 468LN cells using shRNA plasmids. 8 Both 468LN-and VEGF-D-silenced 468LN cells (named DVEGF-D/468LNs) were grown as monolayers in a-MEM supplemented with 10% FBS, 50 U/ml penicillin and 50 mg/ml streptomycin (all materials from GIBCO/ Invitrogen, ON, Canada).
Murine Cell Line C3L5 is a COX-2-expressing, PGE2-, VEGF-C-and VEGF-Dsecreting murine breast cancer cell line produced in our laboratory, the VEGF-C-and -D-secreting ability primarily attributed to COX-2 activity. 25, 27 Cells were maintained in high glucose DMEM (GIBCO, Grand Island, NY, USA) supplemented with 5% fetal bovine serum, 100 U/ml penicillin G and 100 mg/ml streptomycin in a humidified incubator with 5% CO 2 at 37 1C.
Mice Four-to five-week-old athymic nude female mice (Hsd. Athymic Nude-Foxn1 nu /Foxn1 þ , Harlan, IN, USA) and C3H/ HeJ mice (obtained from the Jackson Laboratory) were allowed to acclimatize for 2 weeks, maintained, respectively, in barrier or traditional facilities, on standard mouse chow and tap water on a 12 h light/dark cycle and treated in accordance with the guidelines set by the Canadian Council on Animal Care.
Directed In Vivo Lymphangiogenesis
We significantly modified a directed in vivo angiogenesis assay 23 to measure lymphangiogenesis in addition to angiogenesis. Briefly, sterile angioreactors (Cat. No. 3450-048-01; Trevigen, Gaithersburg, MD, USA) were prechilled at 4 1C and filled with 20 ml of either growth factor-reduced basement membrane extract (BME) (Cat. No. 3450-048-02; Trevigen) alone or 40 Â 10 3 468LN or DVEGF-D/468LN cells in 2 ml a-MEM with 18 ml BME, or 18ml BME with recombinant VEGF-D (20 ng in 2 ml) (622-VD-005; R&D Systems, CA, USA) or FGF-2 (225 ng)/VEGF-A (75 ng) (Cat. No. 3450-048-B10; Trevigen), the latter two used as respective positive controls for lymphangiogenesis and angiogenesis. Angioreactors were incubated at 37 1C for 1 h to allow BME gel formation, before subcutaneous implantation into the Figure 1 ) implanted in the dorsal flank. After the defined experimental period of 10 days, mice were anesthetized to expose the angioreactors. The skin surrounding the angioreactors was cut and opened with fine dissection scissors (Figure 1 ). Evans Blue was injected near the angioreactor to capture images of dye-stained lymphatics immediately and at short intervals up to 25 min with both a digital camera (Nikon, D-90) and a dissection microscope. Subsequently, mice were euthanized humanely to retrieve the angioreactors used for three different purposes (Figure 1) . One of them was carefully removed without severing the ingrowing vessels and excising the rest of the tissues with fine scissors and flash-frozen immediately with dry ice for making cryosections. The other three were removed from the surrounding tissues by excising along the margins to sever any vessel that may be growing into them, and lifting them with dissection forceps. They were used to collect cellular contents and conduct lymphatic ingrowth assay and RNA extraction for real-time gene expression as detailed below.
Evans Blue Dye Tracing
Approximately 2 ml of 4% Evans Blue dye (Sigma-Aldrich, San Francisco, CA, USA) diluted with PBS was injected subcutaneously in nude mice with a 30 G needle at about 2 cm distance from the angioreactor implants, allowing a visual tracing of lymphatics growing into the angioreactors. (e) One angioreactor collected with intact surrounding tissue without disrupting the vascular ingrowth and embedded with OCT compound followed by flash freezing. The remaining three angioreactors were taken out to retrieve cellular contents. (f) Of the latter, one tube was used for immunofluorescence assay and (g) two were used for RNA extraction. DAPI, 4
0 ,6-diamidino-2-phenylindole.
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Images were captured at 5-25 min after injection under a dissection microscope (Nikon SMZ1500).
Retrieval of Cellular Contents from Angioreactors
Under stimulated conditions, lymphatics as well as blood vessels grew into the angioreactors, invading the BME. To quantitate lymphatic vessel ingrowth, angioreactors were removed from the surrounding tissues. The cellular contents were retrieved by cutting one end and squeezing the tube. The tubes were rinsed two times with CellSperse solution (Cat. No. 3450-048-05; Trivigen) to retrieve remaining tissue, which was incubated in 200 ml of the solution for 1 h at 37 1C to digest the BME. The incubation mix was then washed three times with wash buffer (Cat. No. 3450-048-03; Trivigen) and centrifuged (1500 r.p.m. for 5 min) to get a BMEfree cell pellet. The pellet was resuspended in 500 ml a-MEM supplemented with 10% FBS and incubated at 37 1C for 1 h to allow cell surface recovery.
Quantitation of Lymphatic Ingrowth
Each cell pellet was treated with 400 ml DIVAA 1 Â Dilution Buffer (Cat. no. 3450-048-07; Trivigen) and rabbit antimouse Lyve1 antibody (Cat. No. 11-034; AngioBio, Del Mar, CA, USA; diluted 1:500) and incubated at 4 1C overnight. Then, cells were washed three times for 5 min with 1 Â TBST (1 Â PBS/0.3% Triton X-100) and treated with Alexa Fluor 594 (Invitrogen) anti-rabbit secondary antibody (1:5000 dilution) and incubated for another 1 h. After three further washes, cells were resuspended in 200 ml wash buffer and fluorescence was measured in a 96-well plate using a FLUOstar Omega (Bmg Labtech, Fisher Scientific, CA, USA) spectrofluorimeter (excitation 584 nm, emission 620 nm, gain 1500-3000). The mean fluorescence (±s.e.) for 16 replicate assays was determined.
Expression of Lymphatic and Vascular Endothelial Cell Marker mRNAs
In our pilot study with four mice, we observed that the yield of mRNA extracted from cell pellets recovered from a single angioreactor was inadequate. Hence in our definitive experiments, we pooled the contents of two angioreactors from the same mouse (identical condition) ( Figure 1 ). Total RNA was extracted from cell pellets using Qiagen RNeasy (Qiagen, Toronto, ON, Canada). Synthesis of cDNA and quantitative (q) RT-PCR was performed for murine Lyve1 (Mm00475056_m1), Cd31 (Mm01242584_m1) and b-actin (4352933E) genes with TaqMan Gene Expression Assays (Applied Biosystems).
Direct Visualization and Measurements of Lymphangiogenesis and Angiogenesis
The surgically excised tissue including the angioreactor was placed on a disposable vinyl specimen mold, which was then secured and flash frozen on dry ice with OCT compound (Tissue-Tek*, Sakura Finetek USA, Torrance, CA, USA), and the samples were stored at À 20 1C until further processing as follows. Angioreactors were cut longitudinally on a cryostat (Leica CM3050 S) into two halves to place the contents on specimen molds and covered with HistoGel (Thermo Fisher Scientific, Burlington, ON, Canada). Then, the molds were mounted with OCT and frozen again on dry ice. Subsequently, the molds were placed on a cryostat, sections cut at 5-6 mm, and the serial sections picked up on a colorfrost plus slide (Fisher Scientific). Adjacent serial sections were separately stained with hematoxylin/eosin to identify cell morphology, and dual immunostained to visualize lymphatics (Lyve1 or Prox1 or Pdpn staining) and blood vessels (Cd31 staining). To evaluate possible macrophage staining with Lyve1 reported in some studies, 28 sections were also doublestained for Lyve1 and F4/80. All the secondary antibodies and species-specific sera were from Life Technologies (Burlington, ON, Canada). Frozen sections were fixed in ice-cold acetone for 5 min at 4 1C; all of the subsequent steps were performed at room temperature. Slides were rehydrated for 10 min in PBS, followed by incubation for 20 min at room temperature in blocking buffer (5% normal goat serum in PBS with 0.3% Triton X-100) to block nonspecific antibody binding. 25, 29 Three hotspots per section (areas of highest vascular density in the descending order, 24 per group) were identified and examined at Â 400 magnification. The incidence of marker-positive vascular-like structures (irrespective of complete or incomplete lumen, depending on the plane of section) per unit area was scored after setting the threshold for background, using the Image-J software (NIH, Bethesda, MD, USA). 25 The mean values for MVD vs LVD were computed as the staining indices for Cd31 (red) vs Lyve1 or Prox1 (far red, depicted as sky blue), or Cd31 (far red, depicted as sky blue) vs Pdpn (red). We had earlier shown that the 'hotspot' method provides results that are relatively very similar to those provided by the vascular density scores obtained by scanning the total area of the section. 29 Following exactly the same procedure, C3H/HeJ mice received four angioreactors each containing BME and 40 Â 10 3 C3L5 cells in shaven dorsal flank. Mice (two per treatment group) were treated for 9 days before being killed. Treatment regimens included Celecoxib (125 mg/kg by oral gavage, two times daily), or 0.5% methylcellulose (Sigma), which served as the vehicle control. After 9 days, angioreactors retrieved from mice were subjected to dual immunofluorescent labeling for murine Lyve1 (green) and Cd31 (red) in frozen sections. The mean values for MVD and LVD were computed as the staining indices as described above.
Statistics
Data were analyzed using the Sigma Stat (version 3.5; Systat, San Jose, CA, USA). All parametric data were analyzed using a one-way ANOVA and a Tukey-Kramer comparisons post hoc test. A Student's t-test was used to compare two data sets. All statistical tests were two-sided, and data were considered statistically significant at Po0.05.
RESULTS
In this illustrative study, we used MDA-MD-468LN and DVEGF-D/468LN cells to examine the role of VEGF-D expression by tumor cells on tumor-induced lymphangiogenesis in vivo. VEGF-D secretion (24 h, in serum-free medium) by these cells were, respectively, 229.50 pg/ml for 468LN and 48.33 pg/ml for DVEGF-D/468LN, measured by ELISA. 8 In the illustrative study, tubes containing BME alone provided the negative control; those with recombinant Using these five types of implants, we quantified both lymphangiogenesis and angiogenesis with indirect and direct measurements in nude mice as outlined in Figure 1 and detailed in methodology. Figure 3 Lymphatic ingrowth assay and mRNA expression. (a) To determine the temporal kinetics of lymphatic network formation and stability, in a pilot study, four mice (for eachtime point, were killed on days 6, 9 and 12. Levels of lymphatic vessel endothelial hyaluronan receptor-1 (Lyve1) and Cd31 mRNA expression in cellular contents of angioreactor were measured and data presented relative to basement membrane extract (BME) alone. In merged pictures, lymphatics are shown with arrowheads in white and blood vessels in yellow. A few lumens (white arrows) were observed. While significant angiogenesis as well as lymphangiogenesis was evident from all the markers, no significant overlap was noted between Lyve1 and Cd31 staining of endothelial cells. BME, basement membrane extract; DAPI, 4 0 ,6-diamidino-2-phenylindole; VEGF, vascular endothelial growth factor.
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Indirect Measurements
VEGF-D knockdown in tumor cells reduces the density of visible lymphatic network on the surface and ingrowth of lymphatics into the angioreactors Blood vessels including blood capillaries are visibly red because of red cell content. Lymphatic networks are traceable with Evans Blue dye. An abundance of dye-stained lymphatic capillary network was visible around 468LN angioreactor implants (arrowhead) at 10-25 min after injection (Figure 2,  upper panel) . In contrast, in mice implanted with angioreactors containing DVEGF-D/468LN cells, Evans Bluemarked large lymphatics were visible, but lymphatic capillary network around angioreactors were not visible even at 25 min (Figure 2, lower panel, arrowhead) .
To determine initiation of lymphangiogenesis and its temporal kinetics, we conducted a pilot study in a small number of mice. BME and 468LN served as respective negative and positive controls. One mouse per group was killed at each time points on days 6, 9 and 12. Levels of angiogenesis and lymphangiogenesis were measured by quantifying Cd31 and Lyve1 mRNA (Figure 3a ). Significant lymphangiogenesis was detected as early as day 6, increasing to a plateau between days 9 and 12. Thus in the definitive experiments, we killed the mice on day 10.
Red blood cell-containing vasculature within the angioreactors was evident once tubes were exposed. Tubes containing 468LN cells or rVEGF-D alone showed significantly detectable red blood cell content, the highest content observed in the tubes containing FGF-2/VEGF, serving as positive control for angiogenesis. VEGF-D knockdown in 468 LN cells resulted in a marked reduction in red blood cell content (Figure 3b) . Results from immunofluorescence assay for lymphangiogenesis marker Lyve1 (uncorrected for the background provided by BME alone, used as negative control) revealed that Lyve1-labeled murine LECs were recruited into the angioreactors during lymphangiogenesis. Lyve1 signal was significantly greater in cells collected from 468LN angioreactor than DVEGF-D/468LN angioreactor ( Figure 3c ). As expected, the signal was the highest in BME containing rVEGF-D used as positive control for lymphangiogenesis.
VEGF-D knockdown reduces the expression of both murine Lyve1 and Cd31 mRNA
To quantify at mRNA levels indicative of the relative abundance of mouse lymphatics and blood vessels within the angioreactors, we took advantage of the mouse lymphatic endothelial marker Lyve1 and angiogenesis marker Cd31. As expected, implants with FGF-2/VEGF exhibited high Cd31 but very low Lyve1 mRNA, and those with rVEGF-D showed very high Lyve1 but low Cd31 mRNA, whereas implants with BME alone expressed very little of either mRNA. Finally, there was a significant reduction in both Lyve1 and Cd31 mRNA expression in cells collected from DVEGF-D/ 468LN-containing angioreactors, as compared with 468LN angioreactors (Figure 3d ).
Direct Measurements VEGF-D knockdown in 468LN cells reduces both lymphangiogenesis and angiogenesis within the angioreactors
Hematoxylin and eosin-stained sections of angioreactor contents (Figure 4a ) revealed very few cells in BME alone, whereas an abundance of cells inclusive of vascular-like networks was noted in angioreactors containing r-VEGF-D, 468LN or DVEGF-D/468LN cells. Dense vascular-like networks were noted in VEGF-D-containing angioreactors. All three antibodies (Lyve1 or Prox1 or Pdpn) showed specific staining of lymphatic network in sections of angioreactors containing r-VEGF-D, used as positive control for lymphangiogenesis. Blood vessels were stained with Cd31 in the same sections (Figure 4b) . We directly measured the levels of lymphangiogenesis and angiogenesis in serial cryosections of angioreactors with dual immunolabeling for Lyve1 or Prox1 (sky blue) and Cd31 (red) or Pdpn (red) and Cd31 (sky blue), respectively, using the 'hotspots', as reported. The unit scores are the means of three hot spots (as detailed in the Materials and Methods) under each treatment condition, representing the incidence of marker-positive vascular-like structures (with or without complete lumens) per unit area.
High levels of tumor-associated lymphangiogenesis as well as angiogenesis occurred in 468LN-containing implants. Unsurprisingly, many lymphatic and blood vessels coexisted in intimate contact. Incidences of both vascular structures were significantly lower in DVEGF-D/468LN cell-containing implants (images shown in Figure 5a ; quantitation in Figure 5b ). No measurable angiogenesis or lymphangiogenesis was observed in BME-alone implants (data not shown). Some EGFP-tagged 468LN and DVEGF-D/468LN cells (green) were also noted in unlabeled angioreactor sections (Figure 5a ). To test whether macrophages stained for Lyve1 as reported in some studies, 28 some serial sections were also double-stained for F4/80 (red) and Lyve1 (sky blue) ( Figure 6 ). The results showed little or no Lyve1 staining by F4/80-positive cells.
Therapy with COX-2 inhibitor reduces both lymphangiogenesis and angiogenesis within the angioreactor-containing C3L5 cells In 9-day-old implants of C3L5-containing angioreactors in C3H/HeJ mice, data revealed a very high incidence for both Lyve1-and Cd31-stained vascular structures in vehicle-treated mice, which was significantly reduced in Celecoxib-treated mice (Supplementary Figure 1) . These results are highly consistent with our earlier report of inhibition of tumor growth, tumor-associated lymphangiogenesis and angiogenesis and spontaneous metastasis to the lymph nodes and the lungs in this tumor model following Celecoxib therapy. 25 
DISCUSSION
Here we describe a practical, sensitive and quantitative assay for measuring lymphangiogenesis in vivo within a short time frame of 9-10 days utilizing multiple approaches, including direct immunohistochemical identification and scoring of
In this assay, most of our experiments were conducted in nude mice using the MDA-MB-468LN cell line, a lymph node-metastasizing variant of the MDA-MB-468 human breast adenocarcinoma cell line. The assay was further validated with a single experiment using a highly metastatic murine C3L5 breast cancer cell line in immunocompetent mice. In an earlier study, utilizing numerous other in vitro assays and tumor xenotransplants in nude mice, we have defined the multiplicity of mechanisms underlying the capacity of the 468LN cells in promoting lymphangiogenesis, lymphovascular invasion and lymphatic metastasis. 8 We showed that they resulted from the dual overexpression of a9b1-integrin and its ligand VEGF-D by 468LN cells. The limitation of the above-mentioned tumor model is that it is time consuming for the xenograft to produce tumors of appreciable sizes to measure intratumoral lymphangiogenesis. In a syngeneic mouse model of breast cancer expressing both VEGF-C and VEGF-D, in which tumors grew rapidly and quickly metastasized to lymph nodes, the same results were achievable as early as 12 days. 25 We show here that the current assay is equally applicable to this tumor model in immunocompetent mice tested at 9 days. However, xenografted human tumor models being best suited to preclinical testing of drugs, the present assay is ideally suited for such preclinical validation. DIVAA is an excellent well-studied model to measure angiogenic factor-induced angiogenesis or its inhibition with angiostatic agents after implanting angioreactors in the mouse dorsal flank. 23 This is an improvement on the matrigel plug assay as reported by us for tumor-associated angiogenesis, 29 by containing the BME (or matrigel) in a silicon cylinder to direct the ingrowth of newly formed capillaries into the open end of the cylinder. DIVAA has been effectively applied to studies of both proangiogenic 30 and antiangiogenic 24 functions of various agents. We modified and applied this method to quantify lymphangiogenesis and coined the term DIVLA or directed in vivo lymphangiogenesis assay. This method is quick, highly quantitative and can be applied to a variety of studies, including preclinical testing of agents for their ability to block or promote lymphangiogenesis in vivo. As many compounds or tumor cells may have a dual effect on angiogenesis and lymphangiogenesis, as illustrated in this study in the case of VEGF-D, or 468LN or C3L5 cells, its capability for a simultaneous measurement of angiogenesis is an additional advantage. VEGF-D, although well known for its capacity to promote lymphangiogenesis by virtue of binding to VEGF-R3 expressed by lymphatic endothelial precursors, can also bind to VEGF-R2 expressed by vascular endothelial precursors to promote angiogenesis, explaining the dual effect in this study using either 468LN cells (expressing high levels of VEGF-D, but not VEGF-C or VEGF-A) or recombinant VEGF-D in the BME of implanted angioreactors. Knocking down VEGF-D in 468LN cells significantly abrogated both events. This was also the case with Celecoxib therapy in the case of C3L5 cells producing both VEGF-C and VEGF-D, resulting from COX-2 expression. As clearly demonstrated in our results, implants containing growth factor-reduced BME alone showed no sign of angiogenesis or lymphangiogenesis in any of the indirect or direct measurements in our assay, eliminating any role of the matrix in the implanted angioreactors. A simpler matrigel plug assay without the inclusion of angioreactors, in our hands, does not provide as robust results because of the undirected nature of the lymphatic vessel ingrowth, as well as a poorer containment of tumor cells within the implant. Inclusion of tumor cells in the BME within the angioreactor makes its application highly suited for studies of tumor biology and translational cancer research, as has been exploited with the DIVAA model. 22, 23 The role of tumor-associated lymphangiogenesis in lymphatic metastasis has been suggested by an association between tumoral expression of the lymphangiogenic factors VEGF-C or -D and lymphatic metastasis in many epithelial cancers including cancers of the prostate, 31 stomach 32 and the colon. 33 This has been validated by a direct association between intra-or peritumoral lymphangiogenesis with lymphatic invasion and metastasis in cancers of the breast, 4,5 pharynx and larynx. 3 Thus, this assay should have a broad application for preclinical testing of agents with potentials for prevention or intervention of lymphatic metastasis.
Multiple quantitative measurements and markers described in this assay make our model more robust and sensitive compared with the single measurement used for angiogenesis in the original DIVAA assay. 23 We used a variety of approaches such as quantification of the Lyve1 protein by immunofluorescence, Lyve1 mRNA by qPCR from the extracted tissues and direct immunolabeling of frozen sections for multiple markers (Lyve1, Prox1 and Pdpn), all of which gave the same answer, eliminating the limitations of a single approach or a single marker. We found no evidence of Lyve1-stained endothelial linings also staining for Cd31 in our earlier study 25 or this study. To exclude the possibility of Lyve1 staining by macrophages reported in some studies 28 leading to overestimate LVD, we double-stained tissue sections with F4/80 and Lyve1 showing little or no overlap. Furthermore, use of Prox1 13 and Pdpn 12 as additional markers provided very similar results.
This assay can be adapted to a direct testing of the drugs included in the BME along with tumor cells (with drugs with a long half-life), or of drugs given systemically to mice by the enteral or parenteral routes and still get the results in 10 days. There are many drugs that may have no direct effect on the process of lymphangiogenesis, but can block tumor-induced lymphangiogenesis by inhibiting pathways responsible for an upregulation of lymphangiogenic factors such as VEGF-C or VEGF-D produced by tumor cells. For example, expression of COX-2 was shown to upregulate VEGF-C or -D in breast cancer 25, 34 and lung cancer. 35 In the case of breast cancer, this was primarily due to an activation of prostaglandin receptor EP4, so that both COX-2 inhibitor Celecoxib and the EP4 antagonist ONO-AE3-208 given orally were equally effective in blocking tumor-associated lymphangiogenesis and lymphatic metastasis in a COX-2-expressing mouse breast cancer model. 25 In this study, using DIVLA we have Directed in vivo lymphangiogenesis assay M Majumder et al reproduced the effects of Celecoxib therapy in the same tumor noted earlier with the matrigel plug assay. 25 In conclusion, the DIVLA is an innovated version of the DIVAA method for quick and efficient measurements of lymphangiogenesis in combination with angiogenesis. It is highly practicable in laboratories housing nude mice, with training for implanting angioreactors. This implantation is relatively easier in young (6-8 weeks old) nude mice than in immunocompetent mice of similar age, which have a thicker and hairy skin requiring shaving or depilation. The method allows identification of new candidates that regulate lymphatic vasculature, a screening for pro-and antilymphangiogenic agents, and exploring specific mechanisms that underlie or differentially regulate the processes of lymphangiogenesis and angiogenesis. We believe that it presents advancement in vascular biology with the potential of identifying common as well a distinct progenitors and pathways for angiogenesis and lymphangiogenesis. In particular, it offers prospects for the design of strategies and drugs to manipulate the lymphatic system, and thereby intervene the processes of cancer metastasis and lymphedema.
